Sjögren’s Syndrome and the Gut Microbiome: Clinical Links

Sjögren's syndrome is a chronic autoimmune disorder primarily characterised by immune-mediated destruction of the salivary and lacrimal glands, leading to dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca). However, Sjögren's syndrome is now recognised as a systemic disease capable of affecting multiple organs, including the lungs, kidneys, nervous system, joints, and gastrointestinal tract. In recent years, growing research has highlighted the gut microbiome—the diverse community of bacteria, fungi, viruses, and other microorganisms residing within the gastrointestinal tract—as a potential contributor to the development and progression of Sjögren's syndrome.

The gut microbiome plays a vital role in maintaining immune homeostasis

The gut microbiome plays a vital role in maintaining immune homeostasis. A healthy microbiome helps regulate the balance between pro-inflammatory immune responses and immune tolerance through interactions with intestinal epithelial cells and immune cells such as regulatory T cells (Tregs). When this microbial balance is disrupted—a condition known as dysbiosis—it may promote chronic inflammation and increase susceptibility to autoimmune diseases.

Several studies have demonstrated that individuals with Sjögren's syndrome possess a distinctly altered gut microbiome compared with healthy controls. Researchers have reported reduced microbial diversity alongside decreases in beneficial bacteria such as Faecalibacterium prausnitzii, Bifidobacterium, and certain members of the Firmicutes phylum. These organisms are important producers of short-chain fatty acids (SCFAs), particularly butyrate, which helps maintain intestinal barrier integrity and suppress excessive immune activation. Reduced SCFA production may contribute to increased intestinal permeability, commonly referred to as "leaky gut."

Increased intestinal permeability allows bacterial fragments such as lipopolysaccharides (LPS) and other microbial metabolites to enter the bloodstream. These substances can activate the immune system and promote systemic inflammation. In genetically susceptible individuals, this chronic immune stimulation may contribute to the production of autoantibodies, including anti-Ro (SSA) and anti-La (SSB), which are characteristic of Sjögren's syndrome.

The concept of the gut-eye and gut-salivary gland axis has also gained increasing attention. Experimental animal studies have shown that altering the gut microbiome through antibiotics or germ-free environments can worsen autoimmune inflammation affecting tear and saliva production. Conversely, restoration of a healthy microbiome using probiotics or faecal microbiota transplantation has demonstrated improvements in glandular inflammation in experimental models, although human evidence remains limited.

Clinical studies have also identified associations between gut microbial composition and disease severity. Patients with greater dysbiosis often report more severe fatigue, gastrointestinal symptoms, dry eye severity, and systemic inflammatory activity. Many individuals with Sjögren's syndrome also experience irritable bowel syndrome-like symptoms, bloating, constipation, and food sensitivities, suggesting significant interactions between gut health and disease manifestations.

Diet represents one of the most modifiable factors influencing the gut microbiome. Diets rich in dietary fibre, vegetables, legumes, fermented foods, and omega-3 fatty acids encourage the growth of beneficial bacteria and increase SCFA production. While no specific dietary intervention has yet been designed to support Sjögren's syndrome directly, anti-inflammatory dietary patterns such as the Mediterranean diet may help support microbiome diversity and reduce systemic inflammation. Some preliminary studies are also investigating probiotic supplementation, although larger randomised clinical trials are required before firm recommendations can be made.

In conclusion, increasing evidence supports an important relationship between Sjögren's syndrome and the gut microbiome. Dysbiosis, impaired intestinal barrier function, altered immune regulation, and reduced production of beneficial microbial metabolites may all contribute to disease development and symptom severity. Although microbiome-targeted therapies remain an emerging field, improving gut health through nutrition and lifestyle may become an important adjunct to conventional management approaches. Future research will determine whether personalised microbiome interventions can play a greater role in preventing disease progression and improving quality of life for patients living with Sjögren's syndrome.

Get In Touch

https://maxilinreview

https://maxilinreview.com/fingersjones